EirGenix (Taiwan) Performance
| 6589 Stock | TWD 73.50 3.10 4.05% |
The firm shows a Beta (market volatility) of -0.18, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning EirGenix are expected to decrease at a much lower rate. During the bear market, EirGenix is likely to outperform the market. At this point, EirGenix has a negative expected return of -0.19%. Please make sure to confirm EirGenix's treynor ratio, potential upside, and the relationship between the total risk alpha and maximum drawdown , to decide if EirGenix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days EirGenix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 908.3 M | |
| Total Cashflows From Investing Activities | -1.8 B | |
| Free Cash Flow | -199.6 M |
EirGenix |
EirGenix Relative Risk vs. Return Landscape
If you would invest 8,420 in EirGenix on September 14, 2024 and sell it today you would lose (1,070) from holding EirGenix or give up 12.71% of portfolio value over 90 days. EirGenix is generating negative expected returns and assumes 2.4575% volatility on return distribution over the 90 days horizon. Simply put, 21% of stocks are less volatile than EirGenix, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
EirGenix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for EirGenix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as EirGenix, and traders can use it to determine the average amount a EirGenix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0767
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 6589 |
Estimated Market Risk
| 2.46 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average EirGenix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of EirGenix by adding EirGenix to a well-diversified portfolio.
EirGenix Fundamentals Growth
EirGenix Stock prices reflect investors' perceptions of the future prospects and financial health of EirGenix, and EirGenix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EirGenix Stock performance.
| Return On Equity | -5.0E-4 | |||
| Return On Asset | -0.0168 | |||
| Profit Margin | (0) % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | 39.51 B | |||
| Shares Outstanding | 304.26 M | |||
| Price To Book | 4.38 X | |||
| Price To Sales | 25.64 X | |||
| Revenue | 1.7 B | |||
| EBITDA | 164.98 M | |||
| Cash And Equivalents | 626.11 M | |||
| Cash Per Share | 3.70 X | |||
| Debt To Equity | 52.70 % | |||
| Book Value Per Share | 35.17 X | |||
| Cash Flow From Operations | (29.9 M) | |||
| Earnings Per Share | 1.96 X | |||
| Total Asset | 11.44 B | |||
About EirGenix Performance
Evaluating EirGenix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if EirGenix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if EirGenix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
EirGenix Inc. operates as a contract development and manufacturing company worldwide. Its services include cell line development, process development, analytical sciences and quality control, cGMP manufacturing, and antibody drug conjugate. EIRGENIX INC operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 179 people.Things to note about EirGenix performance evaluation
Checking the ongoing alerts about EirGenix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for EirGenix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| EirGenix generated a negative expected return over the last 90 days | |
| The company reported the revenue of 1.7 B. Net Loss for the year was (42.58 M) with profit before overhead, payroll, taxes, and interest of 1.09 B. | |
| EirGenix has accumulated about 626.11 M in cash with (29.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.7. | |
| Roughly 33.0% of the company shares are owned by insiders or employees |
- Analyzing EirGenix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether EirGenix's stock is overvalued or undervalued compared to its peers.
- Examining EirGenix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating EirGenix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of EirGenix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of EirGenix's stock. These opinions can provide insight into EirGenix's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for EirGenix Stock Analysis
When running EirGenix's price analysis, check to measure EirGenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EirGenix is operating at the current time. Most of EirGenix's value examination focuses on studying past and present price action to predict the probability of EirGenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EirGenix's price. Additionally, you may evaluate how the addition of EirGenix to your portfolios can decrease your overall portfolio volatility.